Experimental and theoretical soft x-ray study of nicotine and related compounds

The valence and core electronic structure of nicotine, nicotinic acid, and nicotinamide have been studied by photoelectron and soft X-ray absorption spectroscopy, supported by theoretical calculations, which take into account conformational isomerism. The core-level photoionization spectra of all molecules have been assigned, and theory indicates that the effects of conformational differences are small, generally less than the natural line widths of the core ionic states. However, in the case of nicotinamide, the theoretical valence ionization potentials of cis and trans conformers differ significantly in the outer valence space, and the experimental spectrum is in agreement with the calculated outer valence cis conformer spectrum. In addition, the C, N, and O K edge near-edge absorption fine structure spectra are reported and interpreted by comparison with reference compounds. We find evidence at the N and O K edges of interaction between the delocalized orbitals of the pyridine ring and the substituents for nicotinic acid and nicotinamide. The strength of the interaction varies because the first is planar, while the second is twisted, reducing the extent of orbital mixing

An experimental and theoretical investigation of XPS and NEXAFS of nicotine, nicotinamide, and nicotinc acid

The electronic structures of nicotine, nicotinic acid and nicotinamide have been studied by valence photoemission spectroscopy (PES), core X-ray photoelectron spectroscopy (XPS), and near-edge X-ray absorption fine structure (NEXAFS) and interpreted with the aid of quantum chemical calculations. Nicotinamide and nicotinic acid are closely related and show correspondingly similar spectral features, while nicotine is both structurally and spectroscopically diverse

Lewy body dementia: Overcoming barriers and identifying solutions

Despite its high prevalence among dementias, Lewy body dementia (LBD) remains poorly understood with a limited, albeit growing, evidence base. The public-health burden that LBD imposes is worsened by overlapping pathologies, which contribute to misdiagnosis, and lack of treatments. For this report, we gathered and analyzed public-domain information on advocacy, funding, research outputs, and the therapeutic pipeline to identify gaps in each of these key elements. To further understand the current gaps, we also conducted interviews with leading experts in regulatory/governmental agencies, LBD advocacy, academic research, and biopharmaceutical research, as well as with funding sources. We identified wide gaps across the entire landscape, the most critical being in research. Many of the experts participated in a workshop to discuss the prioritization of research areas with a view to accelerating therapeutic development and improving patient care. This white paper outlines the opportunities for bridging the major LBD gaps and creates the framework for collaboration in that endeavor. HIGHLIGHTS: A group representing academia, government, industry, and consulting expertise was convened to discuss current progress in Dementia with Lewy Body care and research. Consideration of expert opinion,natural language processing of the literature as well as publicly available data bases, and Delphi inspired discussion led to a proposed consensus document of priorities for the field

Lewy body dementia: Overcoming barriers and identifying solutions.

Publication status: PublishedFunder: Lewy Body Dementia Association; doi: http://dx.doi.org/10.13039/100017312Funder: National Institute for Health Research for the Newcastle (NIHR) Biomedical Research CentreFunder: Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia ProgramFunder: Little Family Foundation; doi: http://dx.doi.org/10.13039/100010277Funder: Ted Turner and Family LBD Functional Genomics ConProgramFunder: American Brain Foundation; doi: http://dx.doi.org/10.13039/100005331Funder: Douglas Herthel DVM Memorial FundFunder: GE Healthcare; doi: http://dx.doi.org/10.13039/100006775Despite its high prevalence among dementias, Lewy body dementia (LBD) remains poorly understood with a limited, albeit growing, evidence base. The public-health burden that LBD imposes is worsened by overlapping pathologies, which contribute to misdiagnosis, and lack of treatments. For this report, we gathered and analyzed public-domain information on advocacy, funding, research outputs, and the therapeutic pipeline to identify gaps in each of these key elements. To further understand the current gaps, we also conducted interviews with leading experts in regulatory/governmental agencies, LBD advocacy, academic research, and biopharmaceutical research, as well as with funding sources. We identified wide gaps across the entire landscape, the most critical being in research. Many of the experts participated in a workshop to discuss the prioritization of research areas with a view to accelerating therapeutic development and improving patient care. This white paper outlines the opportunities for bridging the major LBD gaps and creates the framework for collaboration in that endeavor. HIGHLIGHTS: A group representing academia, government, industry, and consulting expertise was convened to discuss current progress in Dementia with Lewy Body care and research. Consideration of expert opinion,natural language processing of the literature as well as publicly available data bases, and Delphi inspired discussion led to a proposed consensus document of priorities for the field